Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041443 | 0.89 | OPRL1 (0.58) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL13041584 | 0.82 | OPRL1 (0.57) | OPRL1OPRM1OPRK1 | |
| SCHEMBL13041544 | 0.77 | PTGDR2 (0.49) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL3735215 | 0.76 | OPRL1 (0.48) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL14272799 | 0.74 | C5AR1 (0.48) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL18729423 | 0.73 | OPRL1 (0.61) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL20989214 | 0.72 | OPRL1 (0.69) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL3178585 | 0.71 | OPRL1 (0.59) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL14595434 | 0.71 | P2RX1 (0.57) | OPRL1OPRM1OPRK1EGLN1C5AR1 | |
| SCHEMBL13041583 | 0.71 | HTR1A (0.47) | OPRL1OPRM1OPRK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | OPRL1 233/4885OPRM1 610/4885OPRK1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.